ARCHIVES

FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint.

This article is from The Cancer Letter archive.

Vol. 32 No. 28 | July 21, 2006

Download PDF Visit The Full Archive

Related Articles

NCI CTEP-Approved Trials For the Month of June

June 27, 2014

In Brief: Brinkley Asks Subcommittee to Add $62.5 Million To NCI Budget for Unfunded Grants

May 11, 1979

Guest Editorial by Robert Cook-Deegan: Myriad Case Ruling Likely to Concur With DOJ Arguments

April 19, 2013

ACS To Offer 10 Nurse Scholarships

July 18, 1980

ODAC Member Critical Of Amgen For Price Incentives.

March 21, 2008

NCI Will Reissue Two RFPs On Smoking TWG Will Hear Artificial Tobacco Work

September 6, 1974